The phase III EAGLE trial evaluated durvalumab, an α–PD-L1 monoclonal antibody, versus durvalumab plus tremelimumab (α–CTLA-4) versus SoC in patients with R/M HNSCC. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.